Crispr Therapeutics Stock News

One of these biotech stocks could have more room to run than the other.

This company is a market leader -- and business is growing.

One of these biotech stocks could have more room to run than the other.

This company is a market leader -- and business is growing.

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $61.84, moving -1.12% from the previous trading session.

It has positive clinical results in hand, a healthy balance sheet, and a strong teammate on its side.

They've already demonstrated their potential to grow without pause for years on end.

If you're willing to speculate, yes.

We've been talking about the growth to value rotation for months. Click here to see why I think that this bull market isn't yet done.

All of them have tremendous growth prospects.

One is a rising star. The other might be more like a constellation.

The stock market and bond market remain historically overvalued today, however, the almost all-encompassing bubble has started to break. Learn more here.

New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving sales of Vertex's (VRTX) triple therapy cystic fibrosis drug, Trikafta/Kaftrio higher.

CRISPR Therapeutics AG (CRSP) shares closed 0.6% lower than its previous 52 week low, giving the company a market cap of $4B. The stock is currently down 14.2% year-to-date, down 67.5% over the past 12 months, and up 192.6% over the past five years. This week, the Dow Jones Industrial Average fell 2.4%, and the S&P 500 fell 2.8%. Trading Activity Trading volume this week was 4.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 508.3% The company's stock price performance over the past 12 months lags the peer average by 605.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

These two biotechs have potential catalysts to look forward to in 2022.